about
Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 InfectionCharacterization of hepatic cytochrome p4503A activity in patients with end-stage renal diseaseCharacterization of tubular functional capacity in humans using para-aminohippurate and famotidine.Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements.Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction.Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines.Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview.Differential aerobic exercise-induced changes in plasma aldosterone between African Americans and Caucasians.Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis.Clinical evaluation of natalizumab for formulary consideration.Performance of a divided-load intravenous vancomycin dosing strategy for critically ill patients.Performance of a divided-load intravenous vancomycin dosing strategy for obese patients.Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010.Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass.Simultaneous determination of p-aminohippuric acid, acetyl-p-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography.Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches.Reply to: "Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling".Estimated GFR vs creatinine clearance for drug dosing.Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection.Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.Renal interaction between itraconazole and cimetidine.Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy.Determination of Rhodamine 123 in cell lysate by HPLC with visible wavelength detection.The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation.Comparison of iothalamate clearance methods for measuring GFR.Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.Disclosure and ethical conduct of clinical research.Determination of famotidine in human plasma and urine by high-performance liquid chromatographyValidation of a simplified method for determination of cimetidine in human plasma and urine by liquid chromatography with ultraviolet detectionUrinary cotinine as an objective measure of cigarette smoking in chronic kidney diseaseDrug adsorption efficacy and palatability of a novel charcoal cookie formulationEffect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir
P50
Q27488869-47B3BDDE-2A12-4729-9CCD-5C8175B30D97Q28202746-93F55B21-4CF3-409B-B0B7-73D922951FE3Q31790315-CD91E1F0-4373-490A-B07C-358E92639A37Q33770199-7F147F73-8A02-43AC-AFB3-B57CDE0ECD0BQ34873261-636A6862-54ED-40F9-BF0F-24479177D80DQ36217672-42721EE8-B1CA-4C17-A441-99F813C23C8BQ36414936-624AD756-B4BC-4429-B511-3F0C5C30AB9EQ36860270-0A6365E4-6617-4383-A5E4-8BFE64AF45B5Q37311092-D6519A69-AB0F-417E-98A2-20FB8DB85515Q37445605-3D2341C3-F1AD-4EE3-91F1-F227874CA817Q37772171-38A94D1B-369F-40FC-907B-32042CFEF1E9Q38164668-739D3EB1-FF8F-4E32-820A-631F7458A156Q38488889-9AB78BF5-2736-4898-BB3C-AD9431E1C548Q38560098-CF41B801-46D7-41AC-B432-0AE708B485FAQ40656918-C6A9A7BD-2C6A-4A29-835F-8DB325250534Q41042343-FCFE4FA1-FF0B-4748-9B8B-151E6E7A0928Q42538149-53D8AA59-941B-4E96-BD48-B424832DD964Q42961049-2CF9EDFF-0184-4A6E-A3FA-BAE07B1C1DF9Q42987347-86D0E74A-97B4-438C-81E5-A12AFBF92D27Q43255869-76AE7D97-C48C-4043-A635-235FE3E0EB73Q43912370-6032B901-BB03-4481-B9C2-1CF96E2637BCQ44097278-6F8BB983-A22B-4EE3-ABF4-52FD4188B979Q45001575-C0F460D3-82F8-4BE3-A76E-E54C9C09FBA7Q45037057-298DF109-2A06-4BA7-86B0-227015005718Q45191658-42A3DA3A-7ACB-469F-BC3D-1A79D12A8A17Q45216467-AE682432-AC8D-46F4-923A-C8CD3DF96C4FQ46197378-1C02D165-4490-440A-A21F-3B678E8BA97DQ46786827-621E25BE-1C34-4BE6-87B6-818ADB5A4B23Q51553270-64882E19-E7BC-4C6F-B458-54CD0EFF5F85Q52914730-635C778F-C714-47AF-B3E7-55B7BCE0771FQ53084468-37FBE05B-39F5-4101-B084-3E2BB976DC1AQ53130688-74F573F5-B31D-44F5-89AD-B635FD02FF54Q73073474-98708B63-1466-432F-A8B2-129B673708F0Q79361958-1749C190-142A-495D-8041-E227C6194197Q79975785-F0420687-D36A-40F3-8650-9A34825F789CQ84959437-1512A51C-74CD-4B94-9ABC-DC9E506D7A45Q86170551-2925818C-47DF-4BB1-9F93-37031E5B6F72
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas C. Dowling
@ast
Thomas C. Dowling
@en
Thomas C. Dowling
@es
Thomas C. Dowling
@sl
type
label
Thomas C. Dowling
@ast
Thomas C. Dowling
@en
Thomas C. Dowling
@es
Thomas C. Dowling
@sl
prefLabel
Thomas C. Dowling
@ast
Thomas C. Dowling
@en
Thomas C. Dowling
@es
Thomas C. Dowling
@sl
P1053
D-2147-2013
P106
P1153
35468514900
P21
P31
P3829
P496
0000-0003-3214-9283